Hepatic osteodystrophy and liver cirrhosis
[ X ]
Tarih
2010
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Baishideng Publishing Group Inc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
AIM: To investigate the correlation between hepatic osteodystrophy and osteoporosis in patients with liver cirrhosis. METHODS: Bone mineral density of the patients (n = 55) and that of the control group (n = 30) were measured by dual-energy X-ray absorptiometry. All the women in the study were premenopausal. Deoxypyridinoline, pyridinoline and urinary Ca2+ were measured as bone destruction markers, while alkaline phosphatase (ALP), osteocalcin and insulin-like growth factor-1 (IGF-1) were measured as bone formation markers. Furthermore, interleukin-1 (IL-1), IL-6, tumor necrosis factor a (TNF-alpha), vitamin D3, direct bilirubin, albumin, cortisol and parathyroid hormone (PTH) levels were measured. The independent Student t test and chi(2) test were employed in comparing both groups, and the Pearson correlation test was used to determine associations. RESULTS: Comparing cirrhosis and control groups, lumbar total T-score (-1.6 +/- 1.2 g/cm(2) vs -0.25 +/- 1.3 g/cm(2), P < 0.001), lumbar total Z-score (-1.2 +/- 1.23 g/cm(2) vs -0.6 +/- 1.3 g/cm(2), P < 0.001), total femur T-score (-0.05 +/- 1 g/cm(2) vs -0.6 +/- 0.9 g/cm(2), P = 0.003) and total femur Z-score (-0.08 +/- 1.5 g/cm(2) vs 0.7 +/- 0.9 g/cm(2), P = 0.003) showed significantly lower values in the cirrhosis group. Blood ALP level (109.2 +/- 57 U/L vs 62.6 +/- 32.5 U/L, P < 0.001), IL-6 level (27.9 +/- 51.6 pg/mL vs 3.3 +/- 3.1 pg/mL, P = 0.01), TNF-alpha level (42.6 +/- 33.2 pg/mL vs 25.3 +/- 12.3 pg/mL, P = 0.007) and direct bilirubin level (0.9 +/- 0.7 mg/dL vs 0.3 +/- 0.2 mg/dL, P < 0.001) were significantly higher in the cirrhosis group. IGF-1 level (47.7 +/- 26.2 ng/mL vs 143.4 +/- 53.2 ng/mL, P < 0.001), osteocalcin level (1.05 +/- 2.5 ng/mL vs 7.0 +/- 13 ng/mL, P = 0.002) and 24 h urinary Ca2+ (169.6 +/- 227.2 mg/dL vs 287 +/- 168.6 mg/dL, P = 0.003) were significantly lower in the cirrhosis group. Urinary deoxypyridinoline/creatinine (9.4 +/- 9.9 pmol/pmol vs 8.1 +/- 5.3 pmolhimol, P = 0.51), urinary pyridinoline/creatinine (51.3 +/- 66.6 pmol/mu mol vs 29 +/- 25.8 pmol/mu mol, P = 0.08), blood IL-1 level (3.4 +/- 8.8 pg/mL vs 1.6 +/- 3.5 pg/mL, P = 0.29), vitamin D3 level (18.6 +/- 13.3 mu g/L vs 18.4 +/- 8.9 mu g/L, P = 0.95), cortisol level (11.1 +/- 4.8 mu g/dL vs 12.6 +/- 4.3 mu g/dL, P = 0.15) and PTH level (42.7 +/- 38 mu g/dL vs 34.8 +/- 10.9 mu g/dL, P = 0.27) were not significantly different. CONCLUSION: Hepatic osteodystrophy is an important complication encountered in patients with liver cirrhosis and all patients should be monitored for hepatic osteodystrophy. (C) 2010 Baishideng. All rights reserved.
Açıklama
Anahtar Kelimeler
Liver Cirrhosis, Osteoporosis, Hepatic Osteodystrophy
Kaynak
World Journal of Gastroenterology
WoS Q Değeri
Q2
Scopus Q Değeri
Q1
Cilt
16
Sayı
13
